Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0001407,
umls-concept:C0003451,
umls-concept:C0005508,
umls-concept:C0014898,
umls-concept:C0033262,
umls-concept:C0035647,
umls-concept:C0050175,
umls-concept:C0184511,
umls-concept:C0205360,
umls-concept:C0220781,
umls-concept:C0220825,
umls-concept:C0243072,
umls-concept:C0442027,
umls-concept:C1533691,
umls-concept:C1883254,
umls-concept:C2603343
|
pubmed:issue |
25
|
pubmed:dateCreated |
1997-1-23
|
pubmed:abstractText |
A new series of hitherto unknown 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA) phosphonodiester derivatives incorporating carboxyesterase-labile S-acyl-2-thioethyl (SATE) moieties as transient phosphonate-protecting groups was prepared in an attempt to increase the oral bioavailability of the antiviral agent PMEA. We report here a direct comparison of the in vitro anti-HIV and anti-HSV activities as well as the in vitro stability between the bis(SATE) derivatives and the already known PMEA prodrugs, namely, bis[(pivaloyloxy)methyl (POM)]- and bis[dithiodiethyl (DTE)]PMEA. All of the compounds tested showed an enhanced in vitro antiviral activity compared to the parent PMEA. The bis(POM)- and bis(tBu-SATE)PMEA derivatives were the most effective. However, striking differences between these two compounds were found during the stability studies. In particular the bis(tBu-SATE)PMEA was found to be more stable than bis(POM)PMEA in human gastric juice and human serum, suggesting it could be considered as a promising candidate for further in vivo development.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adenine,
http://linkedlifedata.com/resource/pubmed/chemical/Antiviral Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Phosphonic Acids,
http://linkedlifedata.com/resource/pubmed/chemical/Prodrugs,
http://linkedlifedata.com/resource/pubmed/chemical/adefovir
|
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0022-2623
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
6
|
pubmed:volume |
39
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
4958-65
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:8960556-Adenine,
pubmed-meshheading:8960556-Administration, Oral,
pubmed-meshheading:8960556-Antiviral Agents,
pubmed-meshheading:8960556-Biological Availability,
pubmed-meshheading:8960556-Cell Line,
pubmed-meshheading:8960556-Drug Stability,
pubmed-meshheading:8960556-Herpesvirus 1, Human,
pubmed-meshheading:8960556-Humans,
pubmed-meshheading:8960556-Magnetic Resonance Spectroscopy,
pubmed-meshheading:8960556-Phosphonic Acids,
pubmed-meshheading:8960556-Prodrugs,
pubmed-meshheading:8960556-Spectrometry, Mass, Fast Atom Bombardment
|
pubmed:year |
1996
|
pubmed:articleTitle |
Synthesis, in vitro antiviral evaluation, and stability studies of bis(S-acyl-2-thioethyl) ester derivatives of 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA) as potential PMEA prodrugs with improved oral bioavailability.
|
pubmed:affiliation |
Laboratoire de Chimie Bioorganique, UMR CNRS-USTL, Université Montpellier II, France.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|